Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

E. David Crawford, Paul F. Schellhammer, David G. McLeod, Judd W. Moul, Celestia S. Higano, Neal Shore, Louis Denis, Peter Iversen, Mario A. Eisenberger, Fernand Labrie

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations


Purpose: Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer. Materials and Methods: We searched PubMed® for clinical trials with the search terms antiandrogens and prostate cancer combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made critical scientific contributions leading to the approval of antiandrogens for treating patients with prostate cancer. Results: Antiandrogens differ in chemical structure and exert varying efficacy and safety profiles. The unfavorable therapeutic index of steroidal antiandrogens led to replacement by safer nonsteroidal agents. Flutamide, nilutamide and bicalutamide, which were designed to target the androgen receptor, were developed primarily for use in combination with castration to provide combined androgen blockade. Modest clinical benefits were observed with the combination of first generation antiandrogens and castration vs castration alone. With increased knowledge of androgen receptor structure and its biological functions a new generation of antiandrogens without agonist activity was designed to provide more potent inhibition of the androgen receptor. Randomized clinical trials in patients with metastatic, castration resistant prostate cancer showed significant survival benefits, which led to the approval of enzalutamide in August 2012. Apalutamide was recently approved while darolutamide is not yet approved in the United States. These next generation antiandrogens are being actively tested in earlier disease states such as nonmetastatic prostate cancer. Evolving knowledge of resistance mechanisms to androgen receptor targeted treatments will stimulate research and drug discovery for additional compounds. Further testing in nonmetastatic castration resistant prostate cancer as well as castration sensitive disease states will hopefully augment our ability to treat a broader spectrum of patients with prostate cancer. Conclusions: Antiandrogens have already provided important benefits for prostate cancer treatment. Greater knowledge about the structural and functional biology of the androgen receptor in prostate cancer will facilitate further discovery and development of further improved antiandrogens with enhanced clinical activity in patients with advanced metastatic disease. Testing these new agents earlier in the course of prostate cancer may further improve the survival and quality of life of patients with current local and/or systemic treatment modalities.

Original languageEnglish (US)
Pages (from-to)956-966
Number of pages11
JournalJournal of Urology
Issue number5
StatePublished - Nov 2018


  • androgen
  • androgen antagonists
  • castration
  • neoplasm metastasis
  • prostatic neoplasms
  • receptors

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens'. Together they form a unique fingerprint.

Cite this